Gamida Cell Ltd (GMDAQ)

[midastouch017]

Gamida Cell price target lowered to $23 from $25 at Piper Sandler Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Gamida Cell to $23 from $25 and keeps an Overweight rating on the shares. With the Highbridge convertible note, Tenthoff estimates Gamida Cell holds pro forma cash of $202M, which will fund operations into the second half of 2022, the analyst tells investors in a research note. Gamida Cell expects to file an IND for GDA-201 and initiate a Phase I/II study in DLBCL and follicular lymphoma in 2H21, the analyst adds.

https://thefly.com/landingPageNews.php?id=3263168&headline=GMDA-Gamida-Cell-price-target-lowered-to--from--at-Piper-Sandler1615310331